Symrise Charts New Course with Record Cash Generation and Shareholder Returns

Symrise achieved record free cash flow of €780M in 2025, funding its first-ever share buyback and a dividend increase, despite a net income dip from impairments.

The flavor and fragrance specialist Symrise delivered a standout operational performance for 2025, marked by a historic shift in capital allocation. While currency headwinds impacted its bottom line, the company achieved a record level of free cash flow, enabling the launch of its first-ever share buyback program alongside a continued dividend increase.

Profitability Gains Amidst Strategic Shifts

Symrise's focus on efficiency over pure volume growth bore fruit in its 2025 financials. Group sales reached €4.93 billion. On a reported basis, this represented a 1.4% decline, but organic growth was a positive 2.8%. The difference is attributed to adverse currency translation effects and smaller portfolio adjustments from strategic divestments.

The core story, however, lies in enhanced profitability. The company's adjusted EBITDA rose to €1.08 billion, with the corresponding margin improving by 120 basis points to 21.9%. This improvement, driven by the ongoing "ONE SYM" transformation initiative, reflects stringent cost management and a favorable product mix.

Net income, however, fell sharply by nearly 48% to €249.3 million. This decrease is due to significant one-off impairments: €148 million related to the terpene business held for sale and a further €150 million on the investment in Swedencare.

Unprecedented Cash Flow Fuels Shareholder Returns

The standout metric for the year was the adjusted business free cash flow, which surged to a record €780 million. This robust cash generation has provided management with the flexibility to initiate a new capital return strategy. A share repurchase program of up to €400 million is now underway and will run until the end of October 2026. Concurrently, the board has proposed raising the dividend to €1.25 per share, which would mark the 16th consecutive annual increase.

Commenting on the results, Barclays analyst Alex Sloane reaffirmed an "Equal Weight" rating with a price target of €84. He noted that management has successfully restored margins and is now, as planned, shifting focus toward growth investments.

Cautious Guidance for the Year Ahead

Looking forward to 2026, Symrise is targeting organic sales growth in a range of 2.0% to 4.0%. The company expects its adjusted EBITDA margin to land between 21.5% and 22.5%. Despite the operational turnaround, the market's initial reaction was muted, with shares down approximately 6% on a weekly basis. The stock currently trades roughly 32% below its 52-week high of over €106, leaving investors to watch whether this operational progress will eventually translate into a sustained share price recovery.